Sign up to our newsletter Subscribe
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
Indication-Based Pricing (IBP)
As more and more medicines come to market with multiple indications or the unrealised potential to treat multiple indications, the way we pay for those medicines becomes critical in making sure we can benefit from them. Indication-based pricing (IBP) permits price to vary according to indication and has been proposed to tackle this issue.
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
